ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
Mutation Research/Genetic Toxicology and Environmental Mutagenesis
Volume 583, Issue 2, 6 June 2005, Pages 105-119
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (404 K)

 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.mrgentox.2005.01.013    How to Cite or Link Using DOI (Opens New Window)
Copyright © 2005 Published by Elsevier B.V.

The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration

V. Koneti Raoa, Turid Knutsena, Thomas Rieda, Darawalee Wangsaa, Bernard Mike Flynnb, Gregory Langhamc, Merrill J. Egorind, Diane Colea, Frank Balisa, Seth M. Steinberga, Susan Batesa and Tito Fojoa, Corresponding Author Contact Information, E-mail The Corresponding Author

aCenter for Cancer Research, National Cancer Institute, NIH, Building 10, Rm 12N226, 9000 Rockville Pike, Bethesda, MD 20892, USA bVeterinary Medicine and Resource Branch, NIMH/NIH, Bethesda, MD 20892, USA cNCI/Division of Laboratory Animals, NCI, NIH, Bethesda, MD 20892, USA dUniversity of Pittsburgh Cancer Center, Pittsburgh, PA 15213, USA

Received 8 April 2004; 
revised 10 December 2004; 
accepted 26 January 2005. 
Available online 27 April 2005.

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Abstract

We utilized a non-human primate model, the rhesus monkey (Macaca mulatta), to quantitate the extent of chromosomal damage in bone marrow cells following chemotherapy. Thiotepa, etoposide, and paclitaxel were chosen as the chemotherapy agents due to their distinct mechanisms of action. Chromosomal aberrations were quantitated using traditional Giemsa stain. We sought to evaluate the extent to which genotoxicity was dependent on the schedule of administration by giving chemotherapy as either a bolus or a 96 h continuous infusion. Neutropenia and areas under the concentration curve (AUCs) were monitored to ensure comparable cytotoxicity and dose administered. At least 100 metaphases were scored in each marrow sample by an investigator unaware of the treatment history of the animals. All three drugs produced a statistically significant higher percentage of abnormal metaphases following bolus chemotherapy (p < 0.0001, p = 0.0015 and p < 0.0001 for thiotepa, etoposide and paclitaxel, respectively). We conclude that infusional administration of thiotepa, etoposide and paclitaxel is less genotoxic to normal bone marrow cells than is bolus administration. These results suggest infusional regimens may be considered where there are concerns about long-term genotoxic sequelae, including secondary cancer, teratogenicity, or possibly the development of drug resistance. We believe this approach provides a reproducible model in which drugs and eventually, regimens can be compared.

Keywords: Drug resistance; Chromosomal damage; Genotoxicity; Secondary malignancies; CIV chemotherapy

Abbreviations: AUCs, areas under the concentration versus time curve; CIV, Continuous intravenous infusion

Article Outline

1. Introduction
2. Methods
2.1. Non-human primate model
2.2. Intravenous access
2.3. Drug doses, schedules and mode of administration
2.4. Monitoring before, during and after chemotherapy infusions
2.5. Study groups and schedule of blood sampling
2.6. Bone marrow sampling and processing
2.7. Statistical methods
2.8. Pharmacokinetics
3. Results
4. Discussion
Acknowledgements
References









 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.